Xcout IntelSign inSubscribe

AMORPHEX THERAPEUTICS HOLDINGS INC. competitors & alternatives

BiotechnologyUnited States

The 12 closest competitors and alternatives to AMORPHEX THERAPEUTICS HOLDINGS INC. among biotechnology companies — ranked by similarity to what AMORPHEX THERAPEUTICS HOLDINGS INC. actually does, not by market-cap band.

12Competitors listed

Subscribe to see AMORPHEX THERAPEUTICS HOLDINGS INC.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

About AMORPHEX THERAPEUTICS HOLDINGS INC.

Amorphex Therapeutics Holdings Inc. develops ocular drug delivery technologies, specifically a patented device called TODDD designed to continuously deliver medication to the eye for multiple months. The device is worn under the eyelid to replace daily eye drop therapy, serving patients with ophthalmic conditions such as glaucoma, retinal diseases, and myopia progression.

AMORPHEX THERAPEUTICS HOLDINGS INC. at a glance

AMORPHEX THERAPEUTICS HOLDINGS INC. is a biotechnology company headquartered in United States. Its most recent funding round raised $265,000 in November 2021. Xcout tracks 5 named people at AMORPHEX THERAPEUTICS HOLDINGS INC., including Robert Thompson (President & CEO).

AMORPHEX THERAPEUTICS HOLDINGS INC. leadership

  • Robert ThompsonPresident & CEO
  • Charles LeahyVice President, Clinical Affairs
  • Edward EllisVice President, Technology
  • Jeanne EllisManager, Chemical Research
  • Kathryn CrawfordVice President, Regulatory and Quality

AMORPHEX THERAPEUTICS HOLDINGS INC. funding rounds

Every round on record:

DateRoundAmountInvestors
SEC Form D filing$265,000—

Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →

Top 12 AMORPHEX THERAPEUTICS HOLDINGS INC. competitors

Ranked by semantic similarity — how close each company is to AMORPHEX THERAPEUTICS HOLDINGS INC. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.

Ocular Therapeutix, Inc.OCUL · BiotechnologyBedford, United States
68% matchPublic

Similar biotechnology company

Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.

Market cap$1.6B
Employees325
Ocular Therapeutix, Inc. competitors & alternatives →

Analyze another company

Search any company we track to see its competitive set.

Or describe a company

Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.

See the full profile of AMORPHEX THERAPEUTICS HOLDINGS INC. and its market

Funding, investors, tech stack, hiring signals, leadership and corporate events — for AMORPHEX THERAPEUTICS HOLDINGS INC.and every competitor above — in one live dashboard.

Subscribe to Xcout Intel →